iZafe Group, in collaboration with Atea Sweden, has won a procurement potentially worth 42-52 MSEK.
STOCKHOLM, SWEDEN / ACCESSWIRE / October 12, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe Group") announces that, in...
Pharmaceutical
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3,NLS to Webcast its...
GE HealthCare Signs $44 Million Contract with BARDA to Develop Artificial Intelligence-Augmented Ultrasound Technology to Aid Clinicians in Diagnosing and Treating Traumatic Injury and Enhance National Preparedness for Mass Casualty Incidents
Advanced ultrasound technology with artificial intelligence applications to support clinicians of all skill levels in efficiently diagnosing lung pathology and...
Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum
Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of...
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
LAVAL, QC / ACCESSWIRE / October 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results...
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live...
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President,...
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under...
AlzeCure Presents Clinical Phase II-Data with ACD440 for Neuropathic Ppain at Pain Conference
STOCKHOLM, SWEDEN / ACCESSWIRE / October 12, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Promore Pharma initiates voluntary liquidation
STOCKHOLM, SE / ACCESSWIRE / October 12, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, October 12, 2023 -- Promore Pharma AB...
Insight Therapeutics Announces Major Expansion in Research Capabilities
NORFOLK, VA / ACCESSWIRE / October 11, 2023 / Insight Therapeutics, LLC, a contract research organization focused on improving the...
Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders
CHICAGO, IL / ACCESSWIRE / October 11, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers
A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast...
Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023
Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and...
CNS Pharmaceuticals’ (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Company on track to achieve value-driving milestones before year-endHOUSTON, TX / ACCESSWIRE / October 11, 2023 / CNS Pharmaceuticals, Inc....
Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
ORLANDO, FL / ACCESSWIRE / October 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal...
Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment...
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Yield10 Bioscience Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina
-On track for commercial launch of first herbicide tolerant Camelina variety as early as 2025 -First field tests of stacked...
NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy
TORONTO and HAIFA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”...